Gainers

• BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million.
• Sionna Therapeutics (NASDAQ:SION) shares rose 22.25% to $6.24. The company's market cap stands at $230.5 million. As per the press release, Q2 earnings came out 4 days ago.
• Dermata Therapeutics (NASDAQ:DRMA) stock increased by 19.44% to $1.29. The company's market cap stands at $4.3 million. As per the news, the Q2 earnings report came out yesterday.
• Intelligent Bio Solutions (NASDAQ:INBS) shares increased by 18.04% to $2.42. The company's market cap stands at $4.9 million.
• Innate Pharma (NASDAQ:IPHA) shares increased by 16.27% to $2.5. The market value of their outstanding shares is at $201.7 million.
• DocGo (NASDAQ:DCGO) stock rose 14.97% to $0.67. The market value of their outstanding shares is at $57.3 million.

Losers

• Silexion Therapeutics (NASDAQ:SLXN) shares declined by 54.6% to $0.47 during Wednesday's regular session. The market value of their outstanding shares is at $1.1 million.
• Bone Biologics (NASDAQ:BBLG) stock decreased by 22.64% to $0.7. The market value of their outstanding shares is at $1.6 million.
• Sutro Biopharma (NASDAQ:STRO) shares fell 21.85% to $19.57. The company's market cap stands at $414.9 million. As per the press release, Q2 earnings came out today.
• Valion Bio (NASDAQ:VBIO) stock declined by 21.23% to $0.24. The company's market cap stands at $1.2 million.
• NeOnc Technologies Hldgs (NASDAQ:NTHI) stock fell 19.55% to $3.5. The company's market cap stands at $112.8 million. The company's, Q2 earnings came out 2 days ago.
• Bolt Biotherapeutics (NASDAQ:BOLT) stock fell 19.35% to $3.21. The market value of their outstanding shares is at $7.6 million. As per the press release, Q2 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.